RxDoctor Payments Data

Bruce Kriegel, MD

Cardiovascular Disease · Brockton, MANPI 1376562447

Payments from drug & device makers

$11,252in general payments, 2019–2025

Across 588 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$797
  • Pfizer$770
  • Johnson & Johnson$643
  • AstraZeneca$607
  • plus $5K from 29 others

What the payments were for

  • Food & beverage$11,18899%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,252 in reported general payments places this provider in the 70th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$208,336
Medicare patients
1,165
Services billed
3,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban523$571,070
XareltoRivaroxaban151$200,080
EntrestoSacubitril/Valsartan82$107,652
Repatha SureclickEvolocumab68$65,458
JardianceEmpagliflozin25$38,439
Metoprolol Succinate523$9,430
Repatha SyringeEvolocumab15$8,871
Ezetimibe173$8,504
Dabigatran EtexilateDabigatran Etexilate Mesylate31$8,128
Rosuvastatin Calcium132$5,764
Atorvastatin Calcium337$5,355
Diltiazem 24hr Er (Cd)Diltiazem Hcl112$4,934
Ranolazine ErRanolazine54$4,799
Flecainide Acetate80$3,827
Valsartan81$3,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$770$571,070523 claims
Johnson & JohnsonXarelto$643$200,080151 claims
NovartisEntresto$1,977$107,65282 claims
Boehringer IngelheimJardiance$573$38,43925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →